Tags : Off Time

Kyowa Kirin’s Istradefylline (KW-6002) Receives EMA’s MAA as an Adjunctive

Vartika Singh January 6, 2020

Shots: The approval is based on trials assessing KW-6002 vs PBO across EU, the US and Japan in patients with PD taking a stable dose of levodopa-based regimens with/out other […]readmore

Tags : Off Time

Kyowa Kirin’s Istradefylline (KW-6002) Receives EMA’s MAA as an Adjunctive

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Off Time

Kyowa Kirin’s Istradefylline (KW-6002) Receives EMA’s MAA as an Adjunctive

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company